Francesco Pellegrino

Francesco Pellegrino

Auto-generated profile, based on publicly available information

Francesco Pellegrino


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2022 in European Urology Focus
Verified
Journal Article
Closed access
FPFrancesco Pellegrino
Francesco Pellegrino
DSDaniel D. Sjoberg
Daniel D. Sjoberg
ATAmy L. Tin
Amy L. Tin
NBNicole E. Benfante
Nicole E. Benfante
ABAlberto Briganti
Alberto Briganti
AVAndrew J. Vickers
Andrew J. Vickers

5 December 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SBSinisa Bratulic
Sinisa Bratulic
ALAngelo Limeta
Angelo Limeta
SDSaeed Dabestani
Saeed Dabestani
HBHelgi Birgisson
Helgi Birgisson
GEGunilla Enblad
Gunilla Enblad
FGFrancesco Gatto
Francesco Gatto
Cancer mortality is exacerbated by late-stage diagnosis. Liquid biopsies based on genomic biomarkers can noninvasively diagnose cancers. However, validation studies have reported ~10% sensitivity to detect stage I cancer in a screening population and specific types, such as brain or genitourinary tumors, remain undetectable. We investigated urine and plasma free glycosaminoglycan profiles (GAGomes) as tumor metabolism biomarkers for multi-cancer early detection (MCED) of 14 cancer types using 2,064 samples from 1,260 cancer or healthy subjects. We observed widespread cancer-specific changes in biofluidic GAGomes recapitulated in an in vivo cancer progression model. We developed three machine learning models based on urine ( N urine = 220 cancer vs. 360 healthy) and plasma ( N plasma = 517 vs. 425) GAGomes that can detect any cancer with an area under the receiver operating characteristic curve of 0.83–0.93 with up to 62% sensitivity to stage I disease at 95% specificity. Undetected patients had a 39 to 50% lower risk of death. GAGomes predicted the putative cancer location with 89% accuracy. In a validation study on a screening-like population requiring ≥ 99% specificity, combined GAGomes predicted any cancer type with poor prognosis within 18 months with 43% sensitivity (21% in stage I; N = 121 and 49 cases). Overall, GAGomes appeared to be powerful MCED metabolic biomarkers, potentially doubling the number of stage I cancers detectable using genomic biomarkers.

27 December 2023 in European Urology Oncology
Verified
Journal Article
Open access
FPFrancesco Pellegrino
Francesco Pellegrino
UFUgo Falagario
Ugo Falagario
SKSophie Knipper
Sophie Knipper
AMAlberto Martini
Alberto Martini
OAOlof Akre
Olof Akre
PWPeter Wiklund
Peter Wiklund
Positive surgical margins (PSMs) are frequent in patients undergoing radical prostatectomy (RP). The impact of PSMs on cancer-specific (CSM) and overall (OM) mortality has not yet been proved definitively. To evaluate whether the presence and the features of PSMs were associated with CSM and OM in patients who underwent robotic-assisted RP. A cohort of 8141 patients underwent robotic-assisted RP with >10 yr of follow-up. Cox multivariable analyses assessed the impact of margin status (positive vs negative) and PSM features (negative vs 3 mm vs multifocal) on the risk of CSM, OM, and biochemical recurrence (BCR) after adjusting for potential confounders. We repeated our analyses after stratifying patients according to clinical (Cancer of the Prostate Risk Assessment [CAPRA] categories) and pathological characteristics (adverse: pT 3-4 and/or grade group [GG] 4-5 and/or pN1 and/or prostate-specific antigen [PSA] persistence). PSMs were found in 1348 patients (16%). Among these, 48 (3.6%) patients had multifocal PSMs. Overall, 1550 men experienced BCR and 898 men died, including 130 for prostate cancer. At Cox multivariable analyses, PSMs were associated with CSM in patients with adverse clinical (Intermediate risk: hazard ratio [HR]: 1.71, p = 0.048; high risk: HR: 2.20, p = 0.009) and pathological (HR: 1.79, p = 0.005) characteristics. Only multifocal PSMs were associated with CSM and OM in the whole population (HR for CSM: 4.68, p < 0.001; HR for OM: 1.82, p = 0.037) and in patients with adverse clinical (intermediate risk: HR for CSM: 7.26, p = 0.006; high risk: HR for CSM: 9.26, p < 0.001; HR for OM: 2.97, p = 0.006) and pathological (HR for CSM: 9.50, p < 0.001; HR for OM: 2.59, p = 0.001) characteristics. Potential limitations include a selection bias and a lack of information on the Gleason score at PSM location. We did not find an association between unifocal PSMs and mortality. Conversely, our results underscore the importance of avoiding multifocal PSMs in patients with adverse clinical (intermediate- and high-risk CAPRA score) and pathological (GG ≥4, pT ≥3, pN1, or PSA persistence) characteristics, to enhance overall survival and reduce CSM. In this study, we evaluated whether the presence and the characteristics of positive surgical margins were associated with mortality in patients who underwent robotic-assisted radical prostatectomy. We found that the presence of positive surgical margins, particularly multifocal margins, was associated with mortality only in patients with adverse clinical and pathological characteristics.

19 October 2022 in European Urology Focus
Verified
Journal Article
Closed access
FPFrancesco Pellegrino
Francesco Pellegrino
ATAmy L. Tin
Amy L. Tin
AMAlberto Martini
Alberto Martini
EVEmily A. Vertosick
Emily A. Vertosick
SPShaun P. Porwal
Shaun P. Porwal
AVAndrew J. Vickers
Andrew J. Vickers

19 October 2023 in European Urology Focus
Verified
Journal Article
Closed access
FPFrancesco Pellegrino
Francesco Pellegrino
ASArmando Stabile
Armando Stabile
GSGabriele Sorce
Gabriele Sorce
LQLeonardo Quarta
Leonardo Quarta
DRDaniele Robesti
Daniele Robesti
GGGiorgio Gandaglia
Giorgio Gandaglia

15 April 2024 in BJU International
Verified
Journal Article
Open access
MLMattia Longoni
Mattia Longoni
PSPietro Scilipoti
Pietro Scilipoti
CRChiara Re
Chiara Re
GRGiuseppe Rosiello
Giuseppe Rosiello
LNLuigi Nocera
Luigi Nocera
MMMarco Moschini
Marco Moschini
Objective: To assess the diagnostic performance of 18F‐fluoro‐2‐deoxy‐ d ‐glucose (18F‐FDG) positron emission tomograpy (PET)/computed tomography (CT) in nodal staging before radical cystectomy (RC) and pelvic lymph node dissection (PLND) for bladder cancer (BCa). Materials and Methods: This analysis was based on a cohort of 199 BCa patients undergoing RC and bilateral PLND between 2015 and 2022. Neoadjuvant chemotherapy (NAC) or immunotherapy (NAI) was administered after oncological evaluation. All patients received preoperative 18F‐FDG PET/CT to assess extravesical disease. Point estimates for true negative, false negative, false positive, true positive, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of conventional imaging and PET/CT were calculated. Subgroup analysis in patients receiving neoadjuvant treatment was performed. Results: At preoperative evaluation, 30 patients (15.1%) had 48 suspicious nodal spots on 18F‐FDG PET/CT. At RC and bilateral PLND, a total of 4871 lymph nodes (LNs) were removed with 237 node metastases corresponding to 126 different regions. Pathological node metastases were found in 17/30 (57%) vs 39/169 patients (23%) with suspicious vs negative preoperative 18F‐FDG PET/CT, respectively (sensitivity = 0.30, specificity = 0.91, PPV = 0.57, NPV = 0.77, accuracy = 0.74). On per‐region analysis including 1367 nodal regions, LN involvement was found in 19/48 (39%) vs 105/1319 (8%) suspicious vs negative regions at PET/CT, respectively (sensitivity = 0.15, specificity = 0.98, PPV = 0.40, NPV = 0.92, ACC = 0.90). Similar results were observed for patients receiving NAC ( n = 44, 32.1%) and NAI ( n = 93, 67.9% [per‐patient: sensitivity = 0.36, specificity = 0.91, PPV = 0.59, NPV = 0.80, accuracy = 0.77; per‐region: sensitivity = 0.12, specificity = 0.98, PPV = 0.32, NPV = 0.93, ACC = 0.91]). Study limitations include its retrospective design and limited patient numbers. Conclusions: In eight out of 10 patients with negative preoperative 18F‐FDG PET/CT, pN0 disease was confirmed at final pathology. No differences were found based on NAC vs NAI treatment. These findings suggest that 18F‐FDG PET/CT could play a role in the preoperative evaluation of nodal metastases in BCa patients, although its cost‐effectiveness is uncertain.